Live Breaking News & Updates on Novartis Gene Therapies

Stay updated with breaking news from Novartis gene therapies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Zolgensma Long-Term Data Demonstrates Sustained Durability for Spinal Muscular Atrophy

Children in the LT-001 study treated after onset achieved or maintained additional milestones up to 7.5 years after 1-time intravenous infusion, Novartis says. ....

Sitra Tauscher Wisniewski , Muscular Dystrophy Association Clinical , Image Credit , Novartis Gene Therapies , Dystrophy Association Clinical , Scientific Conference ,